Expression of mu-BCR-ADL transcripts in chronic neutrophilic leukemia.
The classification of chronic neutrophilic leukemia (CNL) is controversial. Our purpose was to correlate clinical, pathologic, and molecular analyses in 2 cases of CNL. In both cases, the patients were referred because of a substantially increased peripheral WBC count noted during routine examination. Bone marrow biopsies and aspirate smears revealed hypercellularity with myeloid/erythroid ratios of 4:1 and 11:1, respectively. The bone marrow aspirate results were as follows: case 1: blasts, 2%; promyelocytes, 2%; myelocytes, 6%; metamyelocytes, 16%; band neutrophils, 13%; segmented neutrophils, 34%; and case 2: blasts, 1%; promyelocytes, 2%; myelocytes, 15%; metamyelocytes, 20%; band neutrophils, 24%; neutrophils, 19%. Reverse transcriptase in situ polymerase chain reaction studies demonstrated expression of mu-BCR-ABL transcripts in 13% and 25% of the bone marrow cells, respectively. In both cases, the positive signal was noted mainly in the early granulocytic precursors and was present in occasional mature neutrophils. To our knowledge, this is thefirst in situ demonstration of mu-BCR-ABL expression in CNL Ourfindings reinforce the usefulness of this messenger RNA as a molecular marker of CNL.
Cioc
Adina M
AM
Department of Pathology, Ohio State University Medical Center, Columbus 43210, USA.
Nuovo
Gerard J
GJ
D000368:Aged; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D016313:Genes, abl / Q000235:genetics*; D006801:Humans; D017403:In Situ Hybridization; D015467:Leukemia, Neutrophilic, Chronic / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014178:Translocation, Genetic
D012333:RNA, Messenger; D016044:Fusion Proteins, bcr-abl